Chiang, Chi-Ling <br/><br/>
ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model.  [electronic resource] 

 -  Blood  08 2019 
 - 432-444 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood.2018882290  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Biomarkers, Tumor<br/>Cell Cycle Checkpoints--genetics<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>DNA Methylation<br/>Disease Models, Animal<br/>Epigenesis, Genetic<br/>Humans<br/>Immunoconjugates--administration & dosage<br/>Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy<br/>Mice<br/>MicroRNAs--administration & dosage<br/>Nanoparticles--administration & dosage<br/>Receptor Tyrosine Kinase-like Orphan Receptors--antagonists & inhibitors<br/>Survival Rate<br/>Theranostic Nanomedicine<br/>Treatment Outcome<br/>Xenograft Model Antitumor Assays